Bayer and Leica Biosystems ally to produce cancer diagnostic test

Bayer has announced a new collaboration with Leica Biosystems to develop a new companion diagnostic test for cancer patients.

The tests will be based on tissue samples using RNAscope, a multiplex nucleic acid hybridisation technology, and immunohistochemistry for cancer patients.

Leica Biosystems will lend its expertise in assay development, regulatory approval and commercialisation of companion diagnostic tests, based on the automated BOND technology platform for novel targeted cancer therapies developed by Bayer.

By gathering molecular information from individual patients, it will be possible to guide treatment decisions with targeted medications for cancer and other diseases. Early screening for patient-specific tumour markers will also help to design more efficient clinical trials, eventually increasing the overall probability of therapeutic success.

Professor Andreas Busch, member of the executive committee of Bayer's pharmaceuticals division and head of drug discovery, said: "This represents another important step for Bayer towards a more personalised approach in the fight against cancer."

The new agreement is one of a number of partnerships Bayer has with external organisations focused on developing companion diagnostic tests based on blood or tissue samples.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.